These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 9273126

  • 1. [Primary chemoprevention of tuberculosis in HIV-infected patients in non-industrialized countries].
    Anglaret X, Dabis F, Batungwanayo J, Perronne C, Taelman H, Bonard D, Sylla-Koko F, Leroy V, Van de Perre P, Vildé JL, Salamon R.
    Sante; 1997; 7(2):89-94. PubMed ID: 9273126
    [Abstract] [Full Text] [Related]

  • 2. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre.
    Aisu T, Raviglione MC, van Praag E, Eriki P, Narain JP, Barugahare L, Tembo G, McFarland D, Engwau FA.
    AIDS; 1995 Mar; 9(3):267-73. PubMed ID: 7755915
    [Abstract] [Full Text] [Related]

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 4. Influence of the human immunodeficiency virus in the incidence of tuberculosis in a cohort of intravenous drug users: effectiveness of anti-tuberculosis chemoprophylaxis.
    Jansà JM, Serrano J, Caylà JA, Vidal R, Ocaña I, Español T.
    Int J Tuberc Lung Dis; 1998 Feb; 2(2):140-6. PubMed ID: 9580481
    [Abstract] [Full Text] [Related]

  • 5. Reduction of clinical tuberculosis in HIV-infected males with isoniazid prophylaxis.
    Alaei K, Alaei A, Mansouri D.
    East Mediterr Health J; 2002 Nov; 8(6):754-7. PubMed ID: 15568452
    [Abstract] [Full Text] [Related]

  • 6. Active tuberculosis in individuals infected with human immunodeficiency virus after isoniazid prophylaxis.
    Fitzgerald DW, Morse MM, Pape JW, Johnson WD.
    Clin Infect Dis; 2000 Dec; 31(6):1495-7. PubMed ID: 11096020
    [Abstract] [Full Text] [Related]

  • 7. Questions about a placebo-controlled trial of preventive therapy for tuberculosis in HIV-infected Ugandans.
    Desvarieux M.
    N Engl J Med; 1998 Mar 19; 338(12):841; author reply 842-3. PubMed ID: 9508639
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Tuberculosis preventive therapy in HIV-infected persons: feasibility issues in developing countries.
    Hawken MP, Muhindi DW.
    Int J Tuberc Lung Dis; 1999 Aug 19; 3(8):646-50. PubMed ID: 10460096
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Tuberculosis preventive therapy for HIV-infected persons in less developed countries.
    Kritski AL.
    Int J Tuberc Lung Dis; 2000 Feb 19; 4(2 Suppl 1):S76-81. PubMed ID: 10688154
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cost-utility of tuberculosis prevention among HIV-infected adults in Kampala, Uganda.
    Shrestha RK, Mugisha B, Bunnell R, Mermin J, Odeke R, Madra P, Hitimana-Lukanika C, Adatu-Engwau F, Blandford JM.
    Int J Tuberc Lung Dis; 2007 Jul 19; 11(7):747-54. PubMed ID: 17609049
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.